LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES

被引：0
|
作者：
Kaura, S. [1 ]
Dranitsaris, G. [2 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Augmentium Pharma Consulting, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1727
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A508 / A509
页数：2
相关论文
共 50 条
  • [41] A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma.
    Richardson, P
    Schlossman, R
    Munshi, N
    Avigan, D
    Jagannath, S
    Alsina, M
    Doss, D
    McKenney, M
    Hande, K
    Farrell, M
    Gorelik, S
    Colson, K
    Warren, D
    Lunde, L
    Michelle, R
    Cole, G
    Mitsiades, C
    Hideshima, T
    Myers, T
    Knight, R
    Anderson, K
    BLOOD, 2005, 106 (11) : 110A - 111A
  • [42] The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
    Hornberger, John
    Rickert, Joseph
    Dhawan, Ravinder
    Liwing, Johan
    Aschan, Johan
    Lothgren, Mikael
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (06) : 484 - 491
  • [43] Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Kukreti, Vishal
    BLOOD, 2011, 118 (21) : 1266 - 1267
  • [44] Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Trieu, Young
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Chen, Christine
    Prica, Anca
    Tiedemann, Rodger
    Trudel, Suzanne
    Kukreti, Vishal
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (07): : 387 - 394
  • [45] Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma
    Zangari, Maurizio
    Guerrero, Jose
    Cavallo, Federica
    Prasad, H. Keshava
    Esseltine, Dixie
    Fink, Louis
    HAEMATOLOGICA, 2008, 93 (06) : 953 - 954
  • [46] Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.
    Kyrtsonis, MC
    Sachanas, S
    Vassilakopoulos, TP
    Kafassi, N
    Tzenou, T
    Papadogiannis, A
    Kalpadakis, C
    Antoniadis, AG
    Dimopoulou, MN
    Angelopoulou, MK
    Siakantaris, MP
    Dimitriadou, EM
    Kokoris, SI
    Plata, E
    Tsaftaridis, P
    Panayiotidis, P
    Pangalis, GA
    BLOOD, 2005, 106 (11) : 382B - 382B
  • [47] Re: Arcuri and Americo “Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis”
    Faith E. Davies
    Eleanor Saunders
    François Bourhis
    Patricia Guyot
    Annals of Hematology, 2022, 101 : 1599 - 1601
  • [48] Re: Arcuri and Americo "Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis"
    Davies, Faith E.
    Saunders, Eleanor
    Bourhis, Francois
    Guyot, Patricia
    ANNALS OF HEMATOLOGY, 2022, 101 (07) : 1599 - 1601
  • [49] Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple Myeloma: An Indirect Treatment Comparison
    Richardson, Paul G.
    Lee, Jae Hoon
    Majer, Istvan
    Krishna, Arun
    Woodman, Richard C.
    BLOOD, 2014, 124 (21)
  • [50] Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone
    Saboo, Sachin S.
    Fennessy, Fiona
    Benajiba, Lina
    Laubach, Jacob
    Anderson, Kenneth C.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : E175 - E179
12345